Kyver­na Ther­a­peu­tics files for IPO as au­toim­mune CAR-T space heats up

Kyver­na Ther­a­peu­tics, a clin­i­cal-stage biotech ex­am­in­ing CAR-T cell ther­a­py’s po­ten­tial to treat au­toim­mune dis­eases, has filed for an ini­tial pub­lic of­fer­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER